MedTrace Logo

A Pilot Study to Evaluate Safety and Efficacy of CigRx™ in Smokers

NCT01262170 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 109

Last updated 2015-10-30

No results posted yet for this study

Summary

A randomized, double-blind, active-controlled, crossover, pilot study to evaluate the safety and efficacy of CigRx™ Lozenge, a dietary supplement, in daily smokers in temporarily reducing the desire to smoke

Conditions

  • Smoking
  • Tobacco Use Disorder

Interventions

DIETARY_SUPPLEMENT

CigRx Lozenge

lozenge made of dietary supplements

OTHER

Tobacco Lozenge

lozenge made of compressed cured tobacco extract

Sponsors & Collaborators

  • Rock Creek Pharmaceuticals, Inc.

    lead INDUSTRY

Principal Investigators

  • Maria Varga, MD · Star Scientific, Inc

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
23 Years
Max Age
72 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-04-30
Primary Completion
2010-04-30
Completion
2010-04-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01262170 on ClinicalTrials.gov